AbbVie Reports Third-Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
October 30, 2024 7:39 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $3.00, $0.08 better than the analyst estimate of $2.92. Revenue for the quarter came in at $14.46 billion versus the consensus estimate of $14.28 billion.
GUIDANCE:
AbbVie sees FY2024 EPS of $10.90-$10.94, versus the consensus of $10.85.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More